FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

House Democrats Start MS Drug Price Probe

























House Democrats have started what they called an “in-depth” investigation into the pricing of drugs for neurological condition MS, the latest attempt by U.S. politicians to pressure manufacturers to lower costs.

Seven drugmakers -- Biogen Inc., Sanofi, Novartis AG, Roche Holding AG, Bayer AG, Merck KGaA’s EMD Serono unit and Teva Pharmaceuticals Industries Ltd. -- received letters requesting information on pricing strategies from Elijah Cummings and Peter Welch, two representatives who sit on the House Committee on Oversight and Government Reform.

Some pharmaceutical companies appear to be “setting new, higher prices in lockstep with competitors -- a strategy known as ‘shadow pricing,’” Cummings and Welch said, noting that the average annual cost of therapy had increased to more than $60,000 in 2015 from about $16,000 in 2004.

Shares of Biogen, the only U.S.-based company in the group, were down 3.2 percent to $284.66 at 3:23 p.m., amid declines in the stock markets Thursday.

Bayer said in a statement that it doesn’t control the cost for patients at the pharmacy, because copays are determined by insurers and pharmacy-benefit managers -- an argument that pharmaceuticals companies have long made when facing criticism over drug prices.

“We take a lot of care when pricing a medicine,” said Sasha Damouni, a spokeswoman for Bayer. The Leverkusen, Germany-based company will respond directly to the congressmen, she said.

Teva is “analyzing the request in-depth and plan to respond accordingly and fully cooperate with the Committee, said Denise Bradley, a spokeswoman for the Israeli company.

Representatives for the other drugmakers didn’t respond to requests for comment. The letter was made public after business hours in Europe and Israel, where all companies except Biogen are headquartered.

Story Source: The above story is based on materials provided by BLOOMBERG
Note: Materials may be edited for content and length


Go to Newer News Go to Older News